Shield Therapeutics PLC (LON:STX, OTCQX:SHIEF) developer of a breakthrough new product for anaemia, has opened the door to investment from the US with a stock market quote on the OTCQX Best Market.
The drug company has taken on broker-dealer MCAP as market maker and sponsor. It will be listed under the stock ticker SHIEF.
Shield said it will face no additional reporting requirements as a result of the American listing, therefore the additional costs will be “minimal”.
Chief executive Tim Watts said: "With the upcoming launch of Accrufer in the US I believe that Shield will be of increasing relevance to US-based investors.
“By making our shares available on the OTCQX Best Market many US investors should find it easier to buy and sell Shield shares than they would through AIM. Shield's existing shareholders should benefit from this as liquidity increases."
Shield’s main product is Accrufer (known as Feraccru outside the US), which is a stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.